<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOTHROID - levothyroxine sodium tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>LEVOTHROID<span class="Sup">®</span><br>(levothyroxine sodium tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="desc"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">LEVOTHROID<span class="Sup">®</span> (levothyroxine sodium tablets, USP) contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T<span class="Sub">4</span>) sodium].  Synthetic T<span class="Sub">4</span> is identical to that produced in the human thyroid gland.  Levothyroxine (T<span class="Sub">4</span>) sodium has an empirical formula of C<span class="Sub">15</span>H<span class="Sub">10</span>I<span class="Sub">4</span>N NaO<span class="Sub">4</span> × H<span class="Sub">2</span>O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=101de879-bb0a-4157-9c0d-2c5720dd454e&amp;name=levothroid-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inactive"></a><a name="section-3"></a><p></p>
<h1>Inactive Ingredients</h1>
<p class="First">Microcrystalline cellulose, calcium phosphate dibasic, povidone, and magnesium stearate.  The following are the coloring additives per tablet strength.</p>
<a name="i363184ef-0893-4fda-84a0-8d222779c671"></a><table width="100%">
<col align="center" valign="top" width="20%">
<col align="left" valign="top" width="80%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Strength (mcg)</th>
<th class="Rrule" align="center">Color additive(s)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">25 </td>
<td class="Rrule" align="left">FD&amp;C Yellow No. 6 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">50</td>
<td class="Rrule" align="left">None</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">75</td>
<td class="Rrule" align="left">FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">88</td>
<td class="Rrule" align="left">FD&amp;C Yellow No. 6 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10   Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">100</td>
<td class="Rrule" align="left">FD&amp;C Yellow No. 6 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake       </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">112</td>
<td class="Rrule" align="left">D&amp;C Red No. 27 Aluminum Lake, D&amp;C Red No. 30 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">125</td>
<td class="Rrule" align="left">FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, FD&amp;C Yellow No. 6 Aluminum Lake </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">137</td>
<td class="Rrule" align="left">FD&amp;C Blue No. 1 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">150</td>
<td class="Rrule" align="left">FD&amp;C Blue No. 2 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">175</td>
<td class="Rrule" align="left">FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Red No. 30 Aluminum Lake, D&amp;C Red No. 27 Aluminum Lake</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">200</td>
<td class="Rrule" align="left">FD&amp;C Red No. 40 Aluminum Lake</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">300</td>
<td class="Rrule" align="left">FD&amp;C Yellow No. 6 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, D&amp;C Yellow No. 10 Aluminum Lake</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid axis.  Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin-stimulating hormone, TSH, from the anterior pituitary.  TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T<span class="Sub">4</span>) and L-triiodothyronine (T<span class="Sub">3</span>), by the thyroid gland. Circulating serum T<span class="Sub">3</span> and T<span class="Sub">4</span> levels exert a feedback effect on both TRH and TSH secretion.  When serum T<span class="Sub">3</span> and T<span class="Sub">4</span> levels increase, TRH and TSH secretion decrease.  When thyroid hormone levels decrease, TRH and TSH secretion increase.</p>
<p>The mechanisms by which thyroid hormones exert their physiologic actions are not completely understood, but it is thought that their principal effects are exerted through control of DNA transcription and protein synthesis.  T<span class="Sub">3</span> and T<span class="Sub">4</span> diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA.  This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.</p>
<p>Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone.  The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids.  The protein anabolic effects of thyroid hormones are essential to normal growth and development.</p>
<p>The physiological actions of thyroid hormones are produced predominantly by T<span class="Sub">3</span>, the majority of which (approximately 80%) is derived from T<span class="Sub">4</span> by deiodination in peripheral tissues.</p>
<p>Levothyroxine, at doses individualized according to patient response, is effective as replacement or supplemental therapy in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> of any etiology, except transient <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> during the recovery phase of subacute <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
<p>Levothyroxine is also effective in the suppression of pituitary TSH secretion in the treatment or prevention of various types of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">euthyroid goiters</span>, including <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid nodules</span>, Hashimoto's <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>, multinodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> and, as adjunctive therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer (see <span class="Bold"><a href="#usage">INDICATIONS AND USAGE</a></span>, <span class="Bold"><a href="#prec">PRECAUTIONS</a>, <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-4.1"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Absorption of orally administered T<span class="Sub">4</span> from the gastrointestinal (GI) tract ranges from 40% to 80%.   The majority of the levothyroxine dose is absorbed from the jejunum and upper ileum. The relative bioavailability of LEVOTHROID<span class="Sup">®</span> tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 94%.  T<span class="Sub">4</span> absorption is increased by fasting, and decreased in <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndromes</span> and by certain foods such as soybean infant formula. Dietary fiber decreases bioavailability of T<span class="Sub">4</span>. Absorption may also decrease with age.  In addition, many drugs and foods affect T<span class="Sub">4</span> absorption (see <span class="Bold"><a href="#drugint">PRECAUTIONS, Drug Interactions</a></span> and <span class="Bold"><a href="#foodint">Drug-Food Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone.  The higher affinity of both TBG and TBPA for T<span class="Sub">4</span> partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T<span class="Sub">4</span> compared to T<span class="Sub">3</span>.  Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone.  Only unbound hormone is metabolically active.  Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins (see <span class="Bold"><a href="#drugint">PRECAUTIONS, Drug Interactions</a></span> and <span class="Bold"><a href="#drugtest">Drug-Laboratory Test Interactions</a></span>).  Thyroid hormones do not readily cross the placental barrier (see <span class="Bold"><a href="#pregnancy">PRECAUTIONS, Pregnancy</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">T<span class="Sub">4</span> is slowly eliminated (see <span class="Bold"><a href="#t1">Table 1</a></span>).  The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately eighty-percent of circulating T<span class="Sub">3</span> is derived from peripheral T<span class="Sub">4</span> by monodeiodination.  The liver is the major site of degradation for both T<span class="Sub">4</span> and T<span class="Sub">3</span>, with T<span class="Sub">4</span> deiodination also occurring at a number of additional sites, including the kidney and other tissues.   Approximately 80% of the daily dose of T<span class="Sub">4</span> is deiodinated to yield equal amounts of T<span class="Sub">3</span> and reverse T<span class="Sub">3</span> (rT<span class="Sub">3</span>).  T<span class="Sub">3</span> and rT<span class="Sub">3</span> are further deiodinated to diiodothyronine.  Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">Thyroid hormones are primarily eliminated by the kidneys.  A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces.  Approximately 20% of T<span class="Sub">4</span> is eliminated in the stool.  Urinary excretion of T<span class="Sub">4</span> decreases with age.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Hormone</th>
<th class="Rrule" align="center">Ratio in Thyroglobulin</th>
<th class="Rrule" align="center">Biologic Potency</th>
<th class="Rrule" align="center">t<span class="Sub">1/2</span> (days)</th>
<th class="Rrule" align="center">Protein Binding (%)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes TBG, TBPA, and TBA</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>3 to 4 days in <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, 9 to 10 days in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>;</dd>
</dl></td></tr></tfoot>
<tbody><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left">Levothyroxine (T<span class="Sub">4</span>)<br>Liothyronine (T<span class="Sub">3</span>)</td>
<td class="Rrule" align="center">10 - 20<br>1</td>
<td class="Rrule" align="center">1<br>4</td>
<td class="Rrule" align="center">6-7<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br>≤ 2</td>
<td class="Rrule" align="center">99.96<br>99.5</td>
</tr></tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Levothyroxine sodium is used for the following indications:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">As replacement or supplemental therapy in congenital or <span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">acquired hypothyroidism</span> of any etiology, except transient <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> during the recovery phase of subacute <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.  Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and subclinical <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. <span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">Primary hypothyroidism</span> may result from functional deficiency, primary <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Pituitary TSH Suppression</h2>
<p class="First">In the treatment or prevention of various types of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">euthyroid goiters</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>), including <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid nodules</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>), subacute or chronic lymphocytic <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span> (Hashimoto's <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>), multinodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="train"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T<span class="Sub">3</span> and T<span class="Sub">4</span> levels) or overt <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> of any etiology and in patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. Levothyroxine is contraindicated in patients with uncorrected <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> since thyroid hormones may precipitate an acute <span class="product-label-link" type="condition" conceptid="4088744" conceptname="Severe adrenal insufficiency">adrenal crisis</span> by increasing the metabolic clearance of glucocorticoids (see <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>). LEVOTHROID<span class="Sup">®</span> is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the inactive ingredients in LEVOTHROID<span class="Sup">®</span> tablets (see <span class="Bold"><a href="#inactive">DESCRIPTION, Inactive Ingredients</a>.</span>) </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">WARNING: Thyroid hormones, including LEVOTHROID</span><span class="Sup">®</span><span class="Bold">, either alone or with other therapeutic agents, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.  In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effects.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First">Levothyroxine sodium should not be used in the treatment of male or <span class="product-label-link" type="condition" conceptid="197606" conceptname="Female infertility of tubal origin">female infertility</span> unless this condition is associated with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p>In patients with nontoxic diffuse <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> or nodular thyroid disease, particularly the elderly or those with underlying cardiovascular disease, levothyroxine sodium therapy is contraindicated if the serum TSH level is already suppressed due to the risk of precipitating overt <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> (see <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>). If the serum TSH level is not suppressed, LEVOTHROID<span class="Sup">®</span> should be used with caution in conjunction with careful monitoring of thyroid function for evidence of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> and clinical monitoring for potential associated adverse cardiovascular signs and symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="prec"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">Levothyroxine has a narrow therapeutic index.  Regardless of the indication for use, careful dosage titration is necessary to avoid the consequences of over- or under-treatment.  These consequences include, among others, effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Many drugs interact with levothyroxine sodium, necessitating adjustments in dosing to maintain therapeutic response (see <span class="Bold"><a href="#drugint">Drug Interactions</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>Effects on bone mineral density</h3>
<p class="First">In women, long-term levothyroxine sodium therapy has been associated with increased bone resorption, thereby decreasing bone mineral density, especially in post-menopausal women on greater than replacement doses or in women who are receiving suppressive doses of levothyroxine sodium. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase and suppressed serum parathyroid hormone levels. Therefore, it is recommended that patients receiving levothyroxine sodium be given the minimum dose necessary to achieve the desired clinical and biochemical response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<h3>Patients with underlying cardiovascular disease</h3>
<p class="First">Exercise caution when administering levothyroxine to patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span> and to the elderly in whom there is an increased risk of occult cardiac disease.  In these patients, levothyroxine therapy should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease (see <span class="Bold"><a href="#warn">WARNINGS</a></span>; <span class="Bold"><a href="#geriatric">PRECAUTIONS, Geriatric Use</a>; and <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>). If cardiac symptoms develop or worsen, the levothyroxine dose should be reduced or withheld for one week and then cautiously restarted at a lower dose.  Overtreatment with levothyroxine sodium may have adverse cardiovascular effects such as an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> who are receiving levothyroxine therapy should be monitored closely during surgical procedures, since the possibility of precipitating <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may be greater in those treated with levothyroxine.  Concomitant administration of levothyroxine and sympathomimetic agents to patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> may precipitate coronary insufficiency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<h3>Patients with nontoxic diffuse <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> or nodular thyroid disease</h3>
<p class="First">Exercise caution when administering levothyroxine to patients with nontoxic diffuse <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> or nodular thyroid disease in order to prevent precipitation of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span>). If the serum TSH is already suppressed, levothyroxine sodium should not be administered (see <span class="Bold"><a href="#train">CONTRAINDICATIONS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Associated <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<h3>Hypothalamic/pituitary hormone deficiencies</h3>
<p class="First">In patients with secondary or <span class="product-label-link" type="condition" conceptid="45757741" conceptname="Tertiary hypothyroidism">tertiary hypothyroidism</span>, additional hypothalamic/pituitary hormone deficiencies should be considered, and, if diagnosed, treated (see <span class="Bold"><a href="#autoimmune">PRECAUTIONS, Autoimmune polyglandular syndrome</a></span> for <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="autoimmune"></a><a name="section-8.2.2"></a><p></p>
<h3>Autoimmune polyglandular syndrome</h3>
<p class="First">Occasionally, chronic <span class="product-label-link" type="condition" conceptid="135215" conceptname="Hashimoto thyroiditis">autoimmune thyroiditis</span> may occur in association with other <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span> such as <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, and insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients with concomitant <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> should be treated with replacement glucocorticoids prior to initiation of treatment with levothyroxine sodium.  Failure to do so may precipitate an acute <span class="product-label-link" type="condition" conceptid="4088744" conceptname="Severe adrenal insufficiency">adrenal crisis</span> when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may require upward adjustments of their antidiabetic therapeutic regimens when treated with levothyroxine (see <span class="Bold"><a href="#drugint">PRECAUTIONS, Drug Interactions</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Other associated medical conditions</h2>
<p class="First">Infants with <span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">congenital hypothyroidism</span> appear to be at increased risk for other congenital anomalies, with cardiovascular anomalies (<span class="product-label-link" type="condition" conceptid="4209011" conceptname="Pulmonic valve stenosis">pulmonary stenosis</span>, <span class="product-label-link" type="condition" conceptid="4289309" conceptname="Atrial septal defect">atrial septal defect</span>, and <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span>) being the most common association.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="info"></a><a name="section-8.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be informed of the following information to aid in the safe and effective use of LEVOTHROID<span class="Sup">®</span>:</p>
<ol>
<li>Notify your physician if you are allergic to any foods or medicines, are pregnant or intend to become pregnant, are breast-feeding or are taking any other medications, including prescription and over-the-counter preparations.</li>
<li>Notify your physician of any other medical conditions you may have, particularly heart disease, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, and adrenal or pituitary gland problems. Your dose of medications used to control these other conditions may need to be adjusted while you are taking LEVOTHROID<span class="Sup">®</span>. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, monitor your blood and/or urinary glucose levels as directed by your physician and immediately report any changes to your physician. If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently.</li>
<li>Use LEVOTHROID<span class="Sup">®</span> only as prescribed by your physician. Do not discontinue or change the amount you take or how often you take it, unless directed to do so by your physician.</li>
<li>The levothyroxine in LEVOTHROID<span class="Sup">®</span> is intended to replace a hormone that is normally produced by your thyroid gland. Generally, replacement therapy is to be taken for life, except in cases of transient <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, which is usually associated with an <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the thyroid gland (<span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>).</li>
<li>Take LEVOTHROID<span class="Sup">®</span> as a single dose, preferably on an empty stomach, one-half to one hour before breakfast.  Levothyroxine absorption is increased on an empty stomach.</li>
<li>It may take several weeks before you notice an improvement in your symptoms.</li>
<li>Notify your physician if you experience any of the following symptoms: rapid or irregular heartbeat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, heat intolerance, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, changes in menstrual periods, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, or any other unusual medical event.</li>
<li>Notify your physician if you become pregnant while taking LEVOTHROID<span class="Sup">®</span>. It is likely that your dose of LEVOTHROID<span class="Sup">®</span> will need to be increased while you are pregnant.</li>
<li>Notify your physician or dentist that you are taking LEVOTHROID<span class="Sup">®</span> prior to any surgery.</li>
<li>Partial <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> may occur rarely during the first few months of LEVOTHROID<span class="Sup">®</span> therapy, but this is usually temporary.</li>
<li>LEVOTHROID<span class="Sup">®</span> should not be used as a primary or adjunctive therapy in a weight control program.</li>
<li>Keep LEVOTHROID<span class="Sup">®</span> out of the reach of children. Store LEVOTHROID<span class="Sup">®</span> away from heat, moisture, and light.</li>
<li>Agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine sodium tablets. Therefore, levothyroxine sodium tablets should not be administered within 4 hrs of these agents.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="labtests"></a><a name="section-8.5"></a><p></p>
<h2>Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="general"></a><a name="section-8.5.1"></a><p></p>
<h3>General</h3>
<p class="First">The diagnosis of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> is confirmed by measuring TSH levels using a sensitive assay (second generation assay sensitivity ≤ 0.1 mIU/L or third generation assay sensitivity ≤ 0.01 mIU/L) and measurement of free-T<span class="Sub">4</span>.</p>
<p>The adequacy of therapy is determined by periodic assessment of appropriate laboratory tests and clinical evaluation. The choice of laboratory tests depends on various factors including the etiology of the underlying thyroid disease, the presence of concomitant medical conditions, including pregnancy, and the use of concomitant medications (see <span class="Bold"><a href="#drugint">PRECAUTIONS, Drug Interactions</a> and <a href="#drugtest">Drug-Laboratory Test Interactions</a></span>).  Persistent clinical and laboratory evidence of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> despite an apparent adequate replacement dose of LEVOTHROID<span class="Sup">®</span> may be evidence of inadequate absorption, poor compliance, drug interactions, or decreased T<span class="Sub">4</span> potency of the drug product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2"></a><p></p>
<h3>Adults</h3>
<p class="First">In adult patients with primary (thyroidal) <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, serum TSH levels (using a sensitive assay) alone may be used to monitor therapy. The frequency of TSH monitoring during levothyroxine dose titration depends on the clinical situation but it is generally recommended at 6-8 week intervals until normalization. For patients who have recently initiated levothyroxine therapy and whose serum TSH has normalized or in patients who have had their dosage of levothyroxine changed, the serum TSH concentration should be measured after 8-12 weeks. When the optimum replacement dose has been attained, clinical (physical examination) and biochemical monitoring may be performed every 6-12 months, depending on the clinical situation, and whenever there is a change in the patient's status. It is recommended that a physical examination and a serum TSH measurement be performed at least annually in patients receiving LEVOTHROID<span class="Sup">®</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span>, <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>, and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.3"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">congenital hypothyroidism</span>, the adequacy of replacement therapy should be assessed by measuring both serum TSH (using a sensitive assay) and total- or free-T<span class="Sub">4.</span> During the first three years of life, the serum total- or free-T<span class="Sub">4</span> should be maintained at all times in the upper half of the normal range. While the aim of therapy is to also normalize the serum TSH level, this is not always possible in a small percentage of patients, particularly in the first few months of therapy. TSH may not normalize due to a resetting of the pituitary-thyroid feedback threshold as a result of <span class="Italics">in utero </span><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.  Failure of the serum T<span class="Sub">4</span> to increase into the upper half of the normal range within 2 weeks of initiation of LEVOTHROID<span class="Sup">®</span> therapy and/or of the serum TSH to decrease below 20mU/L within 4 weeks should alert the physician to the possibility that the child is not receiving adequate therapy. Careful inquiry should then be made regarding compliance, dose of medication administered, and method of administration prior to raising the dose of LEVOTHROID<span class="Sup">®</span>.</p>
<p>The recommended frequency of monitoring of TSH and total- or free-T<span class="Sub">4</span> in children is as follows: at 2 and 4 weeks after the initiation of treatment; every 1-2 months during the first year of life; every 2-3 months between 1 and 3 years of age; and every 3 to 12 months thereafter until growth is completed.  More frequent intervals of monitoring may be necessary if poor compliance is suspected or abnormal values are obtained.  It is recommended that TSH and T<span class="Sub">4</span>   levels, and a physical examination, if indicated, be performed 2 weeks after any change in LEVOTHROID<span class="Sup">®</span> dosage.  Routine clinical examination, including assessment of mental and physical growth and development, and bone maturation, should be performed at regular intervals (see <span class="Bold"><a href="#pediatric">PRECAUTIONS, Pediatric Use</a> and <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.4"></a><p></p>
<h3>Secondary (pituitary) and tertiary (hypothalamic) <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></h3>
<p class="First">Adequacy of therapy should be assessed by measuring serum free-T<span class="Sub">4</span> levels, which should be maintained in the upper half of the normal range in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="drugint"></a><a name="section-8.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to LEVOTHROID<span class="Sup">®</span>.  In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs.  A listing of drug-thyroidal axis interactions is contained in Table 2.</p>
<p>The list of drug-thyroidal axis interactions in Table 2 may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions.  The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2:  Drug-Thyroidal Axis Interactions</span></caption>
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="center"><span class="Bold">Drug or Drug Class</span></td>
<td class="Rrule" align="center" colspan="2"><span class="Bold">Effect</span></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Drugs that may reduce TSH secretion –the reduction is not sustained; therefore, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> does not occur</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Dopamine / Dopamine Agonists<br>Glucocorticoids<br>Octreotide</td>
<td class="Rrule" align="left" colspan="2">Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: Dopamine ( ≥ 1 µg/kg/min); Glucocorticoids (hydrocortisone ≥ 100 mg/day or equivalent); Octreotide ( &gt; 100 µg/day).</td>
</tr>
<tr><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Drugs that alter thyroid hormone secretion</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="left" colspan="3"><span class="Bold">Drugs that may decrease thyroid hormone secretion, which may result in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Aminoglutethimide<br>Amiodarone<br>Iodide (including iodine-containing  <br> Radiographic contrast agents)<br>Lithium<br>Methimazole<br>Propylthiouracil (PTU)<br>Sulfonamides<br>Tolbutamide</td>
<td class="Rrule" align="left" colspan="2">Long-term lithium therapy can result in <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> in up to 50% of patients, and either subclinical or overt <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, each in up to 20% of patients.  The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span> or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.  Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> than parenterally administered iodinated contrast agents.  Long-term aminoglutethimide therapy may minimally decrease T<span class="Sub">4</span> and T<span class="Sub">3</span> levels and increase TSH, although all values remain within normal limits in most patients.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="left" colspan="3"><span class="Bold">Drugs that may increase thyroid hormone secretion, which may result in <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span></span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Amiodarone<br>Iodide (including iodine-containing  <br> Radiographic contrast agents)</td>
<td class="Rrule" align="left" colspan="2">Iodide and drugs that contain pharmacological amounts of iodide may cause <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> or hyperfunctioning <span class="product-label-link" type="condition" conceptid="4114219" conceptname="Thyroid adenoma">thyroid adenoma</span>).  <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> may develop over several weeks and may persist for several months after therapy discontinuation.  Amiodarone may induce <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> by causing <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Drugs that may decrease T<span class="Sub">4</span> absorption, which may result in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Antacids<br>- Aluminum &amp; Magnesium Hydroxides<br>- Simethicone<br>Bile Acid Sequestrants<br>- Cholestyramine<br>- Colestipol<br>Calcium Carbonate<br>Cation Exchange Resins<br>- Kayexalate<br>Ferrous Sulfate<br>Orlistat<br>Sucralfate</td>
<td class="Rrule" align="left" colspan="2">Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.  Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex.  Administer levothyroxine at least 4 hours apart from these agents. Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function.</td>
</tr>
<tr><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Drugs that may alter T<span class="Sub">4</span> and T<span class="Sub">3</span> serum transport  - but FT<span class="Sub">4</span> concentration remains normal; and, therefore, the patient remains euthyroid</span></td></tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2"><span class="Bold">Drugs that may increase serum TBG concentration</span></td>
<td class="Rrule Toprule" align="left"><span class="Bold">Drugs that may decrease serum TBG concentration</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" colspan="2">Clofibrate<br>Estrogen-containing oral contraceptives<br>Estrogens (oral)<br>Heroin / Methadone<br>5-Fluorouracil<br>Mitotane<br>Tamoxifen</td>
<td class="Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> / Anabolic Steroids<br>Asparaginase<br>Glucocorticoids<br>Slow-Release Nicotinic Acid</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="left" colspan="3"><span class="Bold">Drugs that may cause protein-binding site displacement</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Furosemide ( &gt; 80 mg IV)<br>Heparin<br>Hydantoins<br>Non Steroidal Anti-Inflammatory Drugs<br>- Fenamates<br>- Phenylbutazone<br>Salicylates ( &gt; 2 g/day)</td>
<td class="Rrule" align="left" colspan="2">Administration of these agents with levothyroxine results in an initial transient increase in FT<span class="Sub">4</span>.  Continued administration results in a decrease in serum T<span class="Sub">4</span> and normal FT<span class="Sub">4</span> and TSH concentrations and, therefore, patients are clinically euthyroid.  Salicylates inhibit binding of T<span class="Sub">4</span> and T<span class="Sub">3</span> to TBG and transthyretin.  An initial increase in serum FT<span class="Sub">4</span> is followed by return of FT<span class="Sub">4</span> to normal levels with sustained therapeutic serum salicylate concentrations, although total-T<span class="Sub">4</span> levels may decrease by as much as 30%.</td>
</tr>
<tr><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Drugs that may alter T<span class="Sub">4</span> and T<span class="Sub">3</span> metabolism</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="left" colspan="3"><span class="Bold">Drugs that may increase hepatic metabolism, which  may result  in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Carbamazepine<br>Hydantoins<br>Phenobarbital<br>Rifampin</td>
<td class="Rrule" align="left" colspan="2">Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.  Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T<span class="Sub">4</span> may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="left" colspan="3"><span class="Bold">Drugs that may decrease T<span class="Sub">4</span> 5'-deiodinase activity</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Amiodarone<br>Beta-adrenergic antagonists<br>- (e.g., Propranolol &gt; 160 mg/day)<br>Glucocorticoids<br>- (e.g., Dexamethasone ≥ 4 mg/day)<br>Propylthiouracil (PTU)</td>
<td class="Rrule" align="left" colspan="2">Administration of these enzyme inhibitors decreases the peripheral conversion of T<span class="Sub">4</span> to T<span class="Sub">3</span>, leading to decreased T<span class="Sub">3</span> levels.  However, serum T<span class="Sub">4</span> levels are usually normal but may occasionally be slightly increased.  In patients treated with large doses of propranolol (&gt; 160 mg/day), T<span class="Sub">3</span> and T<span class="Sub">4</span>  levels change slightly, TSH levels remain normal, and patients are clinically euthyroid.  It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.  Short-term administration of large doses of glucocorticoids may decrease serum T<span class="Sub">3</span> concentrations by 30% with minimal change in serum T<span class="Sub">4</span> levels.  However, long-term glucocorticoid therapy may result in slightly decreased T<span class="Sub">3</span> and T<span class="Sub">4</span> levels due to decreased TBG production (see above).</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Miscellaneous</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticoagulants (oral)<br>- Coumarin Derivatives<br>- Indandione Derivatives</td>
<td class="Rrule" align="left" colspan="2">Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants.  Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be carefully monitored in patients taking levothyroxine and oral anticoagulants and the dose of anticoagulant therapy adjusted accordingly.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antidepressants<br>- Tricyclics (e.g., Amitriptyline)<br>- Tetracyclics (e.g., Maprotiline)<br>- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)</td>
<td class="Rrule" align="left" colspan="2">Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.  Toxic effects may include increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and CNS stimulation; onset of action of  tricyclics may be accelerated.  Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antidiabetic Agents<br>- Biguanides<br>- Meglitinides<br>- Sulfonylureas<br>- Thiazolidinediones<br>- Insulin</td>
<td class="Rrule" align="left" colspan="2">Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.  Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cardiac Glycosides</td>
<td class="Rrule" align="left" colspan="2">Serum digitalis glycoside levels may be reduced in <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or when the hypothyroid patient is converted to the euthyroid state.  Therapeutic effect of digitalis glycosides may be reduced.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cytokines<br>- Interferon-α<br>- Interleukin-2</td>
<td class="Rrule" align="left" colspan="2">Therapy with interferon-α has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, or both.  Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.  Interleukin-2 has been associated with transient painless <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span> in 20% of patients.  Interferon-β and -γ have not been reported to cause thyroid dysfunction.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Growth Hormones<br>- Somatrem<br>- Somatropin</td>
<td class="Rrule" align="left" colspan="2">Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure.  However, untreated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> may interfere with growth response to growth hormone.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketamine</td>
<td class="Rrule" align="left" colspan="2">Concurrent use may produce marked <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; cautious administration to patients receiving thyroid hormone therapy is recommended.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methylxanthine Bronchodilators<br>- (e.g., Theophylline)</td>
<td class="Rrule" align="left" colspan="2">Decreased theophylline clearance may occur in hypothyroid patients; clearance returns to normal when the euthyroid state is achieved.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Radiographic Agents</td>
<td class="Rrule" align="left" colspan="2">Thyroid hormones may reduce the uptake of <span class="Sup">123</span>I, <span class="Sup">131</span>I, and <span class="Sup">99m</span>Tc.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sympathomimetics</td>
<td class="Rrule" align="left" colspan="2">Concurrent use may increase the effects of sympathomimetics or thyroid hormone.  Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Chloral Hydrate<br>Diazepam<br>Ethionamide<br>Lovastatin<br>Metoclopramide<br>6-Mercaptopurine<br>Nitroprusside<br>Para-aminosalicylate sodium<br>Perphenazine<br>Resorcinol (excessive topical use)<br>Thiazide Diuretics</td>
<td class="Rrule" align="left" colspan="2">These agents have been associated with thyroid hormone and / or TSH level alterations by various mechanisms.</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1"></a><p></p>
<h3>Oral anticoagulants</h3>
<p class="First">Levothyroxine increases the response to oral anticoagulant therapy.  Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the LEVOTHROID<span class="Sup">®</span> dose is increased.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be closely monitored to permit appropriate and timely dosage adjustments (see <span class="Bold"><a href="#t2">Table 2</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.2"></a><p></p>
<h3>Digitalis glycosides</h3>
<p class="First">The therapeutic effects of digitalis glycosides may be reduced by levothyroxine.  Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides (see <span class="Bold"><a href="#t2">Table 2</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="foodint"></a><a name="section-8.7"></a><p></p>
<h2>Drug-Food Interactions</h2>
<p class="First">Consumption of certain foods may affect levothyroxine absorption thereby necessitating adjustments in dosing.  Soybean flour (infant formula), cotton seed meal, walnuts, and dietary fiber may bind and decrease the absorption of levothyroxine sodium from the GI tract.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="drugtest"></a><a name="section-8.8"></a><p></p>
<h2>Drug-Laboratory Test Interactions</h2>
<p class="First">Changes in TBG concentration must be considered when interpreting T<span class="Sub">4</span> and T<span class="Sub">3</span> values, which necessitates measurement and evaluation of unbound (free) hormone and/or determination of the free-T<span class="Sub">4</span> index (FT<span class="Sub">4</span>I).   Pregnancy, <span class="product-label-link" type="condition" conceptid="4223947" conceptname="Viral hepatitis, type A">infectious hepatitis</span>, estrogens, estrogen-containing oral contraceptives, and <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> increase TBG concentrations. Decreases in TBG concentrations are observed in <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, severe <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, severe liver disease, <span class="product-label-link" type="condition" conceptid="4253197" conceptname="Acromegaly">acromegaly</span>, and after androgen or corticosteroid therapy (see also <span class="Bold"><a href="#t2">Table 2</a></span>).  Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.9"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine.  The synthetic T<span class="Sub">4</span> in LEVOTHROID<span class="Sup">®</span> is identical to that produced naturally by the human thyroid gland.  Although there has been a reported association between prolonged thyroid hormone therapy and breast cancer, this has not been confirmed. Patients receiving LEVOTHROID<span class="Sup">®</span> for appropriate clinical indications should be titrated to the lowest effective replacement dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="pregnancy"></a><a name="section-8.10"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.10.1"></a><p></p>
<h3>Category A</h3>
<p class="First">Studies in women taking levothyroxine sodium during pregnancy have not shown an increased risk of congenital abnormalities. Therefore, the possibility of fetal harm appears remote.  LEVOTHROID<span class="Sup">®</span> should not be discontinued during pregnancy and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> diagnosed during pregnancy should be promptly treated.</p>
<p><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> during pregnancy is associated with a higher rate of complications, including <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, pre-<span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span>. Maternal <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> may have an adverse effect on fetal and childhood growth and development. During pregnancy, serum T4 levels may decrease and serum TSH levels increase to values outside the normal range. Since elevations in serum TSH may occur as early as 4 weeks gestation, pregnant women taking LEVOTHROID<span class="Sup">®</span> should have their TSH measured during each trimester. An elevated serum TSH level should be corrected by an increase in the dose of LEVOTHROID<span class="Sup">®</span>. Since postpartum TSH levels are similar to preconception values, the LEVOTHROID<span class="Sup">®</span> dosage should return to the pre-pregnancy dose immediately after delivery.  A serum TSH level should be obtained 6-8 weeks postpartum.</p>
<p>Thyroid hormones cross the placental barrier to some extent as evidenced by levels in cord blood of athyreotic fetuses being approximately one-third maternal levels. Transfer of thyroid hormone from the mother to the fetus, however, may not be adequate to prevent <span class="Italics">in utero</span> <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nursing"></a><a name="section-8.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Although thyroid hormones are excreted only minimally in human milk, caution should be exercised when LEVOTHROID<span class="Sup">®</span> is administered to a nursing woman. However, adequate replacement doses of levothyroxine are generally needed to maintain normal lactation.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-8.12"></a><p></p>
<h2>Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.12.1"></a><p></p>
<h3>General</h3>
<p class="First">The goal of treatment in pediatric patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> is to achieve and maintain normal intellectual and physical growth and development.</p>
<p>The initial dose of levothyroxine varies with age and body weight (see <span class="Bold"><a href="#t3">DOSAGE AND ADMINISTRATION, Table 3</a></span>). Dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters (see <span class="Bold"><a href="#labtests">PRECAUTIONS, Laboratory Tests</a></span>).</p>
<p>In children in whom a diagnosis of permanent <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> has not been established, it is recommended that levothyroxine administration be discontinued for a 30-day trial period, but only after the child is at least 3 years of age.  Serum T<span class="Sub">4</span> and TSH levels should then be obtained.  If the T<span class="Sub">4</span> is low and the TSH high, the diagnosis of permanent <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> is established, and levothyroxine therapy should be reinstituted.  If the T<span class="Sub">4</span> and TSH levels are normal, euthyroidism may be assumed and, therefore, the <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> can be considered to have been transient. In this instance, however, the physician should carefully monitor the child and repeat the <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> if any signs or symptoms of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> develop.  In this setting, the clinician should have a high index of suspicion of relapse.  If the results of the levothyroxine withdrawal test are inconclusive, careful follow-up and subsequent testing will be necessary.</p>
<p>Since some more severely affected children may become clinically hypothyroid when treatment is discontinued for 30 days, an alternate approach is to reduce the replacement dose of levothyroxine by half during the 30-day trial period.  If, after 30 days, the serum TSH is elevated above 20mU/L, the diagnosis of permanent <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> is confirmed, and full replacement therapy should be resumed.  However, if the serum TSH has not risen to greater than 20mU/L, levothyroxine treatment should be discontinued for another 30-day trial period followed by repeat serum T<span class="Sub">4</span> and TSH testing.</p>
<p>The presence of concomitant medical conditions should be considered in certain clinical circumstances and, if present, appropriately treated (see <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.12.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">Congenital Hypothyroidism</span></h3>
<p class="First"><span class="Underline">(see <span class="Bold"><a href="#labtests">PRECAUTIONS, Laboratory Tests</a> and <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>)</span></p>
<p>Rapid restoration of normal serum T<span class="Sub">4</span> concentrations is essential for preventing the adverse effects of <span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">congenital hypothyroidism</span> on intellectual development as well as on overall physical growth and maturation.  Therefore, LEVOTHROID<span class="Sup">®</span> therapy should be initiated immediately upon diagnosis and is generally continued for life.</p>
<p>During the first 2 weeks of LEVOTHROID<span class="Sup">®</span> therapy, infants should be closely monitored for cardiac overload, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> from avid suckling. </p>
<p>The patient should be monitored closely to avoid undertreatment or overtreatment.  Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment has been associated with <span class="product-label-link" type="condition" conceptid="4210998" conceptname="Craniosynostosis syndrome">craniosynostosis</span> in infants, and may adversely affect the tempo of brain maturation and accelerate the bone age with resultant premature closure of the epiphyses and compromised adult stature.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.12.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">Acquired Hypothyroidism</span> in Pediatric Patients</h3>
<p class="First">The patient should be monitored closely to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height.  Overtreatment may accelerate the bone age and result in <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span> and compromised adult stature.</p>
<p>Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, catch-up growth may not be adequate to normalize adult height.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="geriatric"></a><a name="section-8.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Because of the increased prevalence of cardiovascular disease among the elderly, levothyroxine therapy should not be initiated at the full replacement dose (see <span class="Bold"><a href="#warn">WARNINGS</a></span>, <span class="Bold"><a href="#prec">PRECAUTIONS</a>,</span> and <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions associated with levothyroxine therapy are primarily those of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> due to therapeutic overdosage (see <span class="Bold"><a href="#prec">PRECAUTIONS</a></span> and <span class="Bold"><a href="#over">OVERDOSAGE</a></span>). They include the following:</p>
<p><span class="Bold Italics">General</span>: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, heat intolerance, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>;</p>
<p><span class="Bold Italics">Central nervous system</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>;</p>
<p><span class="Bold Italics">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>;</p>
<p><span class="Bold Italics">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, increased pulse and blood pressure, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, angina, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>;</p>
<p><span class="Bold Italics">Respiratory</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>;</p>
<p><span class="Bold Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and elevations in liver function tests;</p>
<p><span class="Bold Italics">Dermatologic</span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>;</p>
<p><span class="Bold Italics">Endocrine</span>: decreased bone mineral density;</p>
<p><span class="Bold Italics">Reproductive</span>: menstrual irregularities, impaired fertility.</p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span> and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in <span class="product-label-link" type="condition" conceptid="4210998" conceptname="Craniosynostosis syndrome">craniosynostosis</span> in infants and premature closure of the epiphyses in children with resultant compromised adult height.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported rarely with the institution of levothyroxine therapy.</p>
<p>Inadequate levothyroxine dosage will produce or fail to ameliorate the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to inactive ingredients have occurred in patients treated with thyroid hormone products. These include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, various GI symptoms (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to levothyroxine itself is not known to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="over"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The signs and symptoms of overdosage are those of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> (see <span class="Bold"><a href="#prec">PRECAUTIONS</a></span> and <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>).  In addition, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> may occur. <span class="product-label-link" type="condition" conceptid="375557" conceptname="Cerebral embolism">Cerebral embolism</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have occurred in a child ingesting 18 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Treatment of Overdosage</h2>
<p class="First">Levothyroxine sodium should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1.1"></a><p></p>
<h3>Acute Massive Overdosage</h3>
<p class="First">This may be a life-threatening emergency, therefore, symptomatic and supportive therapy should be instituted immediately. If not contraindicated (e.g., by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, or loss of the gag reflex), the stomach should be emptied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage to decrease gastrointestinal absorption. Activated charcoal or cholestyramine may also be used to decrease absorption. Central and peripheral increased sympathetic activity may be treated by administering β-receptor antagonists, e.g., propranolol, provided there are no medical contraindications to their use. Provide respiratory support as needed; control <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>; control <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span> as necessary. Large doses of antithyroid drugs (e.g., methimazole or propylthiouracil) followed in one to two hours by large doses of iodine may be given to inhibit synthesis and release of thyroid hormones. Glucocorticoids may be given to inhibit the conversion of T<span class="Sub">4</span> to T<span class="Sub">3</span>.  Plasmapheresis, charcoal hemoperfusion and exchange transfusion have been reserved for cases in which continued clinical deterioration occurs despite conventional therapy.  Because T<span class="Sub">4</span> is highly protein bound, very little drug will be removed by dialysis.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>General Principles</h2>
<p class="First">The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of LEVOTHROID<span class="Sup">®</span> that is adequate to achieve these goals depends on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>).  Hence, the following recommendations serve only as dosing guidelines.  Dosing must be individualized and adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters (see <span class="Bold"><a href="#labtests">PRECAUTIONS, Laboratory Tests</a></span>).</p>
<p>LEVOTHROID<span class="Sup">®</span> is administered as a single daily dose, preferably one-half to one hour before breakfast. LEVOTHROID<span class="Sup">®</span> should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see <span class="Bold"><a href="#drugint">PRECAUTIONS, Drug Interactions</a></span>).</p>
<p>Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks.</p>
<p>Caution should be exercised when administering LEVOTHROID<span class="Sup">®</span> to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> (see <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Specific Patient Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> in Adults and in Children in Whom Growth and Puberty are Complete (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#labtests">PRECAUTIONS, Laboratory Tests</a></span>)</span></p>
<p>Therapy may begin at full replacement doses in otherwise healthy individuals less than 50 years old and in those older than 50 years who have been recently treated for <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of levothyroxine sodium is approximately 1.7 mcg/kg/day (e.g., <span class="Bold">100-125 mcg/day</span> for a 70 kg adult). Older patients may require less than 1 mcg/kg/day. Levothyroxine sodium doses greater than 200 mcg/day are seldom required. An inadequate response to daily doses ≥ 300 mcg/day is rare and may indicate poor compliance, <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span>, and/or drug interactions.</p>
<p>For most patients older than 50 years or for patients under 50 years of age with underlying cardiac disease, an initial starting dose of <span class="Bold">25-50 mcg/day</span> of levothyroxine sodium is recommended, with gradual increments in dose at 6-8 week intervals, as needed.  The recommended starting dose of levothyroxine sodium in elderly patients with cardiac disease is <span class="Bold">12.5-25 mcg/day</span>, with gradual dose increments at 4-6 week intervals. The levothyroxine sodium dose is generally adjusted in 12.5-25 mcg increments until the patient with <span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">primary hypothyroidism</span> is clinically euthyroid and the serum TSH has normalized.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, the recommended initial levothyroxine sodium dose is <span class="Bold">12.5-25 mcg/day</span> with increases of 25 mcg/day every 2-4 weeks, accompanied by clinical and laboratory assessment, until the TSH level is normalized.</p>
<p>In patients with secondary (pituitary) or tertiary (hypothalamic) <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, the levothyroxine sodium dose should be titrated until the patient is clinically euthyroid and the serum free-T<span class="Sub">4</span> level is restored to the upper half of the normal range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3>Pediatric Dosage</h3>
<p class="First"><span class="Underline">Congenital or <span class="product-label-link" type="condition" conceptid="138384" conceptname="Acquired hypothyroidism">Acquired Hypothyroidism</span> (see <span class="Bold"><a href="#labtests">PRECAUTIONS, Laboratory Tests</a></span>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.1"></a><p></p>
<h4>General Principles</h4>
<p class="First">In general, levothyroxine therapy should be instituted at full replacement doses as soon as possible.  Delays in diagnosis and institution of therapy may have deleterious effects on the child's intellectual and physical growth and development.</p>
<p>Undertreatment and overtreatment should be avoided (see <span class="Bold"><a href="#pediatric">PRECAUTIONS, Pediatric Use</a></span>). </p>
<p>LEVOTHROID<span class="Sup">®</span> may be administered to infants and children who cannot swallow intact tablets by crushing the tablet and suspending the freshly crushed tablet in a small amount (5-10 mL or 1-2 teaspoons) of water. This suspension can be administered by spoon or dropper.  <span class="Bold">DO NOT STORE THE SUSPENSION</span>.  Foods that decrease absorption of levothyroxine, such as soybean infant formula, should not be used for administering levothyroxine sodium tablets (see <span class="Bold"><a href="#foodint">PRECAUTIONS, Drug-Food Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.2"></a><p></p>
<h4>Newborns</h4>
<p class="First">The recommended starting dose of levothyroxine sodium in newborn infants is <span class="Bold">10-15 mcg/kg/day</span>. A lower starting dose (e.g., 25 mcg/day) should be considered in infants at risk for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (&lt; 5 mcg/dL) or undetectable serum T<span class="Sub">4</span> concentrations, the recommended initial starting dose is <span class="Bold">50 mcg/day</span> of levothyroxine sodium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.3"></a><p></p>
<h4>Infants and Children</h4>
<p class="First">Levothyroxine therapy is usually initiated at full replacement doses, with the recommended dose per body weight decreasing with age (see <span class="Bold"><a href="#t3">Table 3</a></span>).  However, in children with chronic or severe <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, an initial dose of <span class="Bold">25 mcg/day</span> of levothyroxine sodium is recommended with increments of 25 mcg every 2-4 weeks until the desired effect is achieved.</p>
<p><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span> in an older child can be minimized if the starting dose is one-fourth of the recommended full replacement dose, and the dose is then increased on a weekly basis by an amount equal to one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Levothyroxine Sodium Dosing Guidelines for Pediatric <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></span></caption>
<col align="left" valign="top" width="56%">
<col align="center" valign="top" width="44%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="center">AGE</th>
<th class="Rrule" align="center">Daily Dose Per Kg Body Weight<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>The dose should be adjusted based on clinical response and laboratory parameters (<span class="Bold">see <a href="#labtests">PRECAUTIONS, Laboratory Tests</a> and <a href="#pediatric">Pediatric Use</a></span>).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">  0-3 months</span></td>
<td class="Rrule" align="center"><span class="Bold">10-15 mcg/kg/day</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  3-6 months</span></td>
<td class="Rrule" align="center"><span class="Bold">8-10 mcg/kg/day</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  6-12 months</span></td>
<td class="Rrule" align="center"><span class="Bold">6-8   mcg/kg/day</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  1-5 years</span></td>
<td class="Rrule" align="center"><span class="Bold">5-6   mcg/kg/day</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  6-12 years</span></td>
<td class="Rrule" align="center"><span class="Bold">4-5   mcg/kg/day</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  &gt;12 years but growth and puberty incomplete </span></td>
<td class="Rrule" align="center"><span class="Bold">2-3 mcg/kg/day</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">  Growth and puberty complete</span></td>
<td class="Rrule" align="center"><span class="Bold">1.7 mcg/kg/day</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.4"></a><p></p>
<h4>Pregnancy</h4>
<p class="First">Pregnancy may increase levothyroxine requirements (see <span class="Bold"><a href="#pregnancy">Pregnancy</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.5"></a><p></p>
<h4>Subclinical <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h4>
<p class="First">If this condition is treated, a lower levothyroxine sodium dose (e.g., <span class="Bold">1 mcg/kg/day</span>) than that used for full replacement may be adequate to normalize the serum TSH level. Patients who are not treated should be monitored yearly for changes in clinical status and thyroid laboratory parameters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.6"></a><p></p>
<h4>TSH Suppression in Well-differentiated Thyroid Cancer and <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">Thyroid Nodules</span></h4>
<p class="First">The target level for TSH suppression in these conditions has not been established with controlled studies. In addition, the efficacy of TSH suppression for benign nodular disease is controversial. Therefore, the dose of LEVOTHROID<span class="Sup">®</span> used for TSH suppression should be individualized based on the specific disease and the patient being treated.</p>
<p>In the treatment of well-differentiated (papillary and follicular) thyroid cancer, levothyroxine is used as an adjunct to surgery and radioiodine therapy. Generally, TSH is suppressed to &lt;0.1 mU/L, and this usually requires a levothyroxine sodium dose of <span class="Bold">greater than 2 mcg/kg/day</span>. However, in patients with high-risk tumors, the target level for TSH suppression may be &lt;0.01 mU/L.</p>
<p>In the treatment of benign <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> and nontoxic multinodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, TSH is generally suppressed to a higher target (e.g., 0.1 to either 0.5 or 1.0 mU/L) than that used for the treatment of thyroid cancer. Levothyroxine sodium is contraindicated if the serum TSH is already suppressed due to the risk of precipitating overt <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> (see <span class="Bold"><a href="#train">CONTRAINDICATIONS</a>, <a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#prec">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2.7"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">Myxedema Coma</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">Myxedema coma</span> is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Therefore, oral thyroid hormone drug products are not recommended to treat this condition. Thyroid hormone drug products formulated for intravenous administration should be administered.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">‑‑‑LEVOTHROID<span class="Sup">®</span> (levothyroxine sodium tablets, USP) are supplied as caplet-shaped, color-coded, potency marked tablets in 12 strengths:</span></p>
<a name="ifb36d903-b31f-44d1-8c0c-d010c1c28aad"></a><table width="60%"><tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Strength (mcg)</span><br>
</td>
<td>
<span class="Bold">Color</span><br>
</td>
<td>
<span class="Bold">Bottles of</span><br>
</td>
<td>
<span class="Bold">NDC Code</span><br>
</td>
</tr>
<tr>
<td>150<br>
</td>
<td>Blue<br>
</td>
<td>30<br>
</td>
<td>54868-4602-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-4602-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-4602-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>175<br>
</td>
<td>Lilac<br>
</td>
<td>30<br>
</td>
<td>54868-4918-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-4918-1<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-4918-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>200<br>
</td>
<td>Pink<br>
</td>
<td>30<br>
</td>
<td>54868-5312-2<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>90<br>
</td>
<td>54868-5312-0<br>
</td>
</tr>
<tr>
<td><br></td>
<td><br></td>
<td>100<br>
</td>
<td>54868-5312-1<br>
</td>
</tr>
<tr class="Last">
<td><br></td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
</tbody></table>
<br><div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>STORAGE CONDITIONS</h2>
<p class="First">Store at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F)</p>
<p>Protect from moisture and light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">MANUFACTURED for:</span><br>Forest Pharmaceuticals, Inc. <br>Subsidiary of Forest Laboratories, Inc.<br>St. Louis, MO  63045</p>
<p><span class="Bold">by:</span><br>LLOYD PHARMACEUTICAL<br>Division of Lloyd, Inc.<br>Shenandoah, IA 51601</p>
<p>REV<span class="Bold">:</span> June 2011</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma         74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mcg Tablet Bottle Label</h1>
<p class="First"><br></p>
<p><span class="Bold">Levothroid<span class="Sup">®</span></span><br>(levothyroxine sodium tablets, USP)</p>
<p><span class="Bold">150 mcg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mcg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=101de879-bb0a-4157-9c0d-2c5720dd454e&amp;name=4602.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 175 mcg Tablet Bottle Label</h1>
<p class="First"><br></p>
<p><span class="Bold">Levothroid<span class="Sup">®</span></span><br>(levothyroxine sodium tablets, USP)</p>
<p><span class="Bold">175 mcg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 175 mcg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=101de879-bb0a-4157-9c0d-2c5720dd454e&amp;name=4918.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mcg Tablet Bottle Label</h1>
<p class="First"><br></p>
<p><span class="Bold">Levothroid<span class="Sup">®</span></span><br>(levothyroxine sodium tablets, USP)</p>
<p><span class="Bold">200 mcg</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mcg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=101de879-bb0a-4157-9c0d-2c5720dd454e&amp;name=5312.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHROID 		
					</strong><br><span class="contentTableReg">levothyroxine sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4602(NDC:0456-1325)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM</td>
<td class="formItem">150 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (caplet-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">150;T4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4602-0</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4602-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4602-2</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021116</td>
<td class="formItem">03/08/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHROID 		
					</strong><br><span class="contentTableReg">levothyroxine sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4918(NDC:0456-1326)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM</td>
<td class="formItem">175 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 27</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (lilac) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (caplet-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">175;T4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4918-0</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4918-1</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4918-2</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021116</td>
<td class="formItem">09/12/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHROID 		
					</strong><br><span class="contentTableReg">levothyroxine sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5312(NDC:0456-1327)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM</td>
<td class="formItem">200 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (caplet-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">200;T4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5312-0</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5312-1</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5312-2</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021116</td>
<td class="formItem">05/20/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dba74198-1341-41e1-9f6e-a756104c434b</div>
<div>Set id: 101de879-bb0a-4157-9c0d-2c5720dd454e</div>
<div>Version: 2</div>
<div>Effective Time: 20120302</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
